GNH USA

Europe — EMA

Mulpleo (Lusutrombopag)

GNH USA supplies Mulpleo (Lusutrombopag), a thrombopoietin receptor agonist for thrombocytopenia in liver disease undergoing procedures. Request a quote.

Lusutrombopag

Request sourcing

1
Pack/s

What is Lusutrombopag?

Lusutrombopag, the active ingredient in Mulpleo, is a thrombopoietin receptor agonist presented as an oral tablet for oral administration. It is indicated for the management of thrombocytopenia in liver disease patients who are scheduled for invasive procedures, helping to raise platelet counts prior to surgery.

GNH USA supplies Mulpleo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets and supporting clinical needs across Europe and other regions.

What is Lusutrombopag used for?

Lusutrombopag is a thrombopoietin receptor agonist used to treat conditions related to low platelet counts.

- Thrombocytopenia in chronic liver disease undergoing invasive procedures: Increases platelet count to reduce bleeding risk before surgery.

What are the side effects of Lusutrombopag?

Lusutrombopag may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate head pain reported during therapy. - Nausea: occasional feeling of stomach upset. - Fatigue: general tiredness experienced by some patients. - Diarrhea: loose stools occurring in a minority of users. - Abdominal pain: discomfort in the stomach area. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Thrombosis: formation of abnormal blood clots, potentially life‑threatening. - Severe hepatic dysfunction: marked liver enzyme elevations or failure. - Anaphylaxis: rare severe allergic reaction requiring immediate medical attention. - Myocardial infarction: rare heart attack events. - Portal vein thrombosis: clot formation in the portal vein. - Severe bleeding: unexpected hemorrhage despite platelet increase.

What precautions apply to Lusutrombopag?

When prescribing Lusutrombopag, clinicians should consider several safety precautions. - Dose adjustment: Use caution in patients with severe hepatic impairment. - Bleeding risk: Monitor platelet counts before and after treatment to assess efficacy and safety. - Thrombotic risk: Assess for personal or family history of thrombosis prior to initiation. - Pregnancy: Use only if the potential benefit justifies the potential risk; data are limited. - Drug interactions: Review concomitant medications that affect platelet function or metabolism. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

What does Lusutrombopag interact with?

Lusutrombopag can interact with other medicines, requiring attention to potential effects on efficacy and safety.

Major Interactions (Avoid): - Concurrent use with other thrombopoietin receptor agonists: may increase risk of excessive platelet rise. - Strong CYP3A4 inducers (e.g., rifampin): may reduce lusutrombopag exposure and effectiveness. - Anticoagulants (e.g., warfarin): may alter bleeding risk and require close monitoring.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): monitor for additive bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal bleeding potential. - Herbal supplements affecting platelet function (e.g., ginkgo biloba): monitor platelet response.

Frequently asked questions

What is Mulpleo used for?+
Mulpleo contains the active ingredient lusutrombopag and is prescribed to increase platelet counts in patients with chronic liver disease who need to undergo invasive medical or surgical procedures. By raising platelet levels, it helps reduce the risk of bleeding during these interventions.
How does lusutrombopag work?+
Lusutrombopag acts as an agonist of the thrombopoietin (TPO) receptor, known as c‑Mpl, on bone‑marrow megakaryocyte precursors. Activation of this receptor triggers signaling pathways that stimulate megakaryocyte proliferation and maturation, leading to increased production of platelets.
What is the usual dose of Mulpleo?+
The dosage of Mulpleo is individualized by the treating physician based on the patient’s platelet count, liver function, and the planned procedure. The prescriber determines the appropriate strength, frequency, and duration of therapy in accordance with clinical guidelines.
Is Mulpleo safe during pregnancy or breastfeeding?+
Safety data for lusutrombopag in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.
How do I order Mulpleo from GNH USA?+
To request Mulpleo, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Mulpleo compare with the main alternative drug or class?+
The primary alternative to lusutrombopag is avatrombopag, another oral thrombopoietin receptor agonist. Both agents increase platelet counts, but they differ in dosing schedules, metabolic pathways, and specific regulatory approvals. Clinicians choose based on patient characteristics, drug‑interaction profile, and local prescribing guidelines.
How should Mulpleo be stored and handled?+
Mulpleo tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.
How is Mulpleo administered?+
Mulpleo is taken orally as a tablet with a glass of water. It is usually administered on a specific day before the planned invasive procedure, as directed by the prescribing physician, and should be swallowed whole without crushing or chewing.
What are the most serious risks associated with Mulpleo?+
Serious risks include the development of thrombosis (including portal vein thrombosis), severe hepatic dysfunction, and rare cases of anaphylaxis or myocardial infarction. Patients should be monitored closely for signs of abnormal clot formation or liver injury during treatment.
Who should not use Mulpleo?+
Mulpleo is contraindicated in patients with known hypersensitivity to lusutrombopag or any tablet excipients, those with active uncontrolled thrombotic disorders, and individuals with severe hepatic impairment where the drug’s safety has not been established. A thorough medical history should be reviewed before initiation.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lusutrombopag
Route
Oral Use
Manufacturer
Shionogi B.V.
Origin
EU

Related products

Mulpleo

Mulpleo

Lusutrombopag

Shionogi B.V.
EU
Mulpleo

Mulpleo

Lusutrombopag

Shionogi B.V.
EU
Mulpleo

Mulpleo

Lusutrombopag

Shionogi B.V.
EU